– Allogeneic HCT activity recovered sharply in 2023 after COVID-era declines, with the largest growth in patients aged 65–74 years (CIBMTR 2013–2023).
– Matched unrelated donors remain the single largest allogeneic donor source (45%), but haploidentical and mismatched unrelated donor use has risen as PTCy-based GVHD prophylaxis has been widely adopted.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
